Sanofi Announces FDA Approval for Auvi-Q
Sanofi (NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Auvi-Q is the first-and-only compact epinephrine auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.